⌕
Harmony Biosciences Holdings · HRMY · Nasdaq
Tenet 81 · Strong
Compare
$33.01+0.15%At closeTenet 81 · Strong
$33.01+0.05 (+0.15%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Harmony Biosciences Holdings (HRMY) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~29.9%/yr (FY21→FY25), net margin 18.3%, and free cash flow (~$347.9M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲21.5%
868.5
FY21→FY25CAGR +29.9%/yr
Net income ($M)▲9.1%
158.7
one-off year: see footnoteCAGR +46.3%/yr
Free cash flow ($M)▲87.4%
347.9
FY21→FY25CAGR +37.2%/yr
Diluted EPS▲8.0%
2.71
FY21→FY25CAGR +47.0%/yr
What the receipts whisper · what a headline number hides
Share count
−1.1%

59.2mn → 58.5mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$310.0K

−99.1% YoY in FY25 · 0.0% of revenue.

Returns vs FCF
0%

$0.0M returned vs $347.9M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)868.5Revenue−198.3COGS670.1Gross profit−189.6R&D−152.5SG&A208.5Op income−49.8Tax & other158.7Net income

18¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 81.8% → 77.2%. Net margin 18.3% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
989,360.0868,453.0714,734.0582,022.0437,855.0305,440.0▲21.5%+29.9%
Cost of revenue
256,941.0198,342.0156,815.0121,236.083,481.055,518.0▲26.5%+37.5%
Gross profit
732,419.0670,111.0557,919.0460,786.0354,374.0249,922.0▲20.1%+28.0%
Research & development
237,575.0189,594.0145,825.076,063.070,886.030,367.0▲30.0%+58.1%
Selling, general & admin
145,769.0152,536.0110,352.095,289.084,017.063,909.0▲38.2%+24.3%
Total operating expenses
513,058.0461,642.0367,093.0268,756.0234,188.0162,394.0▲25.8%+29.8%
Operating incomefeeds ROC rank
219,361.0208,469.0190,826.0192,030.0120,186.087,528.0▲9.2%+24.2%
Other income, net
13,600.06,595.0978.0−18,634.0−15,500.0−50,100.0——
Pretax income
232,961.0215,064.0191,804.0173,396.0104,686.037,428.0▲12.1%+54.8%
Income tax
54,360.056,377.046,311.044,543.0−76,782.02,831.0▲21.7%+111.2%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
178,601.0158,687.0145,493.0128,853.0181,468.034,597.0▲9.1%+46.3%
Per share
Diluted EPSbuyback-sensitive
3.022.712.512.132.970.58▲8.0%+47.0%
Diluted shares (mn)
59.6858.5457.8760.3761.1059.21▲1.2%−0.3%
Margins
Gross margin66th pct in Healthcare
74.0%77.2%78.1%79.2%80.9%81.8%▼0.9pp−4.7pp
Operating margin
22.2%24.0%26.7%33.0%27.4%28.7%▼2.7pp−4.7pp
Net margin81st pct in Healthcare
18.1%18.3%20.4%22.1%41.4%11.3%▼2.1pp+6.9pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 8% vs a 24% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was −73% vs a 24% norm for this window, likely a one-time item; see the filing.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Harmony Biosciences Holdings' revenue last fiscal year?

Harmony Biosciences Holdings reported revenue of $868.5M in fiscal 2025, up 21.5% from fiscal 2024.

What was Harmony Biosciences Holdings' net income?

Harmony Biosciences Holdings reported net income of $158.7M in fiscal 2025, a net margin of 18.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.